Erratum: Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation (Oncotarget)

Karam Khaddour; Joshua Dowling; Jiayi Huang; Martha Council; David Chen; Lynn Cornelius; Tanner Johanns; Sonika Dahiya; George Ansstas

doi:10.18632/oncotarget.28365

Erratum: Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation (Oncotarget)

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	126
Number of pages	1
Journal	Oncotarget
Volume	14
DOIs	https://doi.org/10.18632/oncotarget.28365
State	Published - Feb 11 2023

Access to Document

10.18632/oncotarget.28365

Cite this

Khaddour, K., Dowling, J., Huang, J., Council, M., Chen, D., Cornelius, L., Johanns, T., Dahiya, S., & Ansstas, G. (2023). Erratum: Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation (Oncotarget). Oncotarget, 14, 126. https://doi.org/10.18632/oncotarget.28365

@article{dcc87559a4d0409cb82b382a7cc7cde5,

title = "Erratum: Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation (Oncotarget)",

author = "Karam Khaddour and Joshua Dowling and Jiayi Huang and Martha Council and David Chen and Lynn Cornelius and Tanner Johanns and Sonika Dahiya and George Ansstas",

year = "2023",

month = feb,

day = "11",

doi = "10.18632/oncotarget.28365",

language = "English",

volume = "14",

pages = "126",

journal = "Oncotarget",

issn = "1949-2553",

}

Khaddour, K, Dowling, J , Huang, J , Council, M, Chen, D, Cornelius, L , Johanns, T , Dahiya, S & Ansstas, G 2023, 'Erratum: Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation (Oncotarget)', Oncotarget, vol. 14, pp. 126. https://doi.org/10.18632/oncotarget.28365

TY - JOUR

T1 - Erratum

T2 - Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation (Oncotarget)

AU - Khaddour, Karam

AU - Dowling, Joshua

AU - Huang, Jiayi

AU - Council, Martha

AU - Chen, David

AU - Cornelius, Lynn

AU - Johanns, Tanner

AU - Dahiya, Sonika

AU - Ansstas, George

PY - 2023/2/11

Y1 - 2023/2/11

UR - https://www.scopus.com/pages/publications/85148113251

U2 - 10.18632/oncotarget.28365

DO - 10.18632/oncotarget.28365

M3 - Comment/debate

C2 - 36780317

AN - SCOPUS:85148113251

SN - 1949-2553

VL - 14

SP - 126

JO - Oncotarget

JF - Oncotarget

ER -

Erratum: Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation (Oncotarget)

Access to Document

Other files and links

Cite this